Testing Services for Drug Development

We Provide a Unique Range of Integrated Testing Services to Support Biopharmaceutical Drug Development

Sartorius Stedim BioOutsource are a leading provider of cGMP, GLP, and GCP compliant contract testing services for the global biopharmaceutical industry. Our extensive suite of services combined with our technical and regulatory expertise make us the preferred choice for outsourcing your testing needs and accelerating your drug development program.

Discover Our Expert Solutions

Nivolumab Biosimilars

Sartorius offers a complete ready to use characterization package for anti-PD-1 biosimilars, saving time and development cost on the path to market.

Learn More

Off-The-Shelf Assays

Reduce your biosimilar time to market with our high quality off-the-shelf assays

Learn More

Custom Assay Development

Can't find an assay for your molecule? No problem, we can develop a custom one for you

Learn More

Biosafety Testing

As leaders of cGMP and GLP biosafety testing we ensure your product is compliant with regulatory standards to ensure it is free of contaminants

Learn More

Discover Our Comprehensive Range of Testing Services

Analytical Testing for Innovator Molecules

We have a long history in providing product characterization for innovative new therapeutics, with over 10 years' experience in delivering testing for innovator products. We are experts in the development, optimization, and validation of complex cell based potency bioassays and binding assays. Coupled with our expertise in protein characterization provides a full range of integrated services for your New Biological Entity (NBE).

Discover more about how we can support your innovator molecule.

Analytical Testing for Biosimilars

We are the market leader for biosimilar testing, supporting over 230 biosimilar development projects within our industry-leading portfolio of off-the-shelf cell based bioassays and binding assays, which we are continually expanding. Our clients appreciate our integrated service offering, providing you with one point of contact from DNA to clinic.

We provide off-the-shelf assays, custom assays, and biosafety testing for both biosimilar and innovator molecules. Our scientists are highly experience experts, and can provide technical and regulatory guidance and support throughout your drug development project.

Nivolumab (Opdivo®️) and Anti-PD-1 Molecules

Checkpoint inhibitors have gained more traction as an essential mechanism in the treatment of cancer. Programmed cell death protein 1 (PD-1) is an immune checkpoint found on cells involved in regulating the immune system's response to self-cells by down-regulating the immune response and promoting self-tolerance by suppressing T cell inflammatory activity. Therefore, PD-1 has a vital role in preventing autoimmune diseases but can also prevent the immune system from killing cancer cells.

Nivolumab, a fully human IgG4 molecule and other anti-PD-1 molecules, has revolutionized cancer treatment by acting as checkpoint inhibitors, blocking the interaction between PD-1 and its ligand (PD-L1 and PD-L2), which would typically lead to the inhibition of T cell activation. Biosimilars have the potential to provide more affordable healthcare and expand patient access to biologics. 

Consult Our Experts

Available Assays

Sartorius offers a complete characterization package for innovator and biosimilar nivolumab, increasing speed to market while reducing biosimilar manufacturers' in-house development costs. Sartorius can build a package to suit your characterization needs from structure to binding to function.





Ig Subtype 












ELISA Binding 




FACS (binding) 



Reporter Bioassay 











T Cell Proliferation/Activation 



T cell Exhaustion 



Structural Analysis and Confirmation 






Your Data

Related Content

Cell Line Development

Learn More

Characterize Your Cell Banks

Learn More

Providing Service Excellence

Learn More